Abcam, ab315822, Anti-AAV8 + AAV9 antibody [HL2372] - BSA and Azide free

Size: 100µg / 1mg
Mouse Recombinant Monoclonal AAV8 antibody. Carrier free. Suitable for I-ELISA, Dot and reacts with Recombinant fragment - Adeno-associated virus - 8, Recombinant fragment - Adeno-associated virus 9 samples.
Key facts
Host species:Mouse,
Clonality:Monoclonal,
Clone number:HL2372,
Isotype:IgG2a,
Carrier free:Yes,
Reacts with:Adeno-associated virus - 8, Adeno-associated virus 9,
Applications:Dot, I-ELISASee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab315822 is the carrier-free version of
ab315821
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.
Want a custom formulation?
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Adeno-associated virus serotypes AAV8 and AAV9 are types of non-enveloped viruses. They belong to the Parvoviridae family and show varied capsid (protein shell) structures which influence their host interactions and applications in gene therapy. The mass of the AAV capsid is approximately 25 kilodaltons. These viruses target a wide range of tissues with AAV8 showing strong tropism for liver tissue and AAV9 having extensive distribution including the central nervous system and cardiac tissues. In experimental settings AAV variants are frequently used due to their efficiency and safety in delivering genetic material into cells for gene therapy.
Biological function summary
AAV8 and AAV9 are versatile vectors that carry therapeutic genes to specific cells without integrating into the host genome. They are not known to cause any human disease which makes them attractive in clinical applications. AAV9 for instance can cross the blood-brain barrier allowing it to reach neurological targets efficiently. Although these vectors do not function as part of a larger biological complex their ability to encapsulate expression cassettes distinguishes them from other viral vectors enhancing their use in targeting diverse genetic disorders.
Pathways
AAV8 and AAV9 are critical tools in gene transfer technology leveraging various mechanisms such as endocytosis to enter target cells. They primarily participate in pathways involving the transduction of encoded genetic material avoiding integration into the host DNA. AAV8 has displayed efficient interaction with hepatic pathways while AAV9 is linked with neuronal pathways due to its ability to cross the blood-brain barrier. These serotypes potentially interact with specific cellular receptors or transport proteins during their entry and trafficking within host cells facilitating targeted gene delivery.
AAV8 and AAV9 have become prominent in studies targeting genetic conditions like muscular dystrophy and spinal muscular atrophy. AAV9's ability to penetrate neural tissues makes it a valuable vector for treating neurological disorders such as these. Additionally AAV8 is often used in liver-related diseases where its strong liver-targeting properties play a significant role. The effectiveness of these serotypes in delivering genes to specific tissues has solidified their role in therapeutic strategies working in conjunction with proteins involved in the pathogenesis of these disorders.